Literature DB >> 23771700

Effects of glial cell line-derived neurotrophic factor on microRNA expression in a 6-hydroxydopamine-injured dopaminergic cell line.

Li Li1, Huizhen Chen, Fangfang Chen, Feng Li, Meng Wang, Li Wang, Yunqing Li, Dianshuai Gao.   

Abstract

Parkinson's disease (PD) is the second most prevalent, progressive neurodegenerative disease and is characterized by the irreversible and selective loss of nigrostriatal dopaminergic (DA) neurons. Glial cell line-derived neurotrophic factor (GDNF), which is a potent protective factor for DA neurons, is considered a promising neuroprotective candidate for PD. microRNAs (miRNAs) have been shown to be involved in a number of neurodegenerative diseases. Both miRNAs and GDNF affect DA neuronal processes, but the molecular crosstalk between these molecules remains unclear. The present study aimed to evaluate whether GDNF modulates miRNA expression. We used microarray analysis and real-time polymerase chain reaction (RT-PCR) to investigate miRNAs expression in 6-hydroxydopamine (6-OHDA)-injured MN9D cells treated with GDNF for 30 min, 1 h, or 3 h. Our results showed that GDNF treatment led to differential expression of 143 miRNAs. To further identify mechanisms by which GDNF exerts its effects, we compared miRNAs and mRNAs microarray data at the 1-h time point. We found that various biological processes and pathways were regulated at the miRNA level following GDNF treatment. Collectively, these results provide evidence of the capacity of GDNF to influence miRNAs expression, suggesting a new mechanism of GDNF action.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771700     DOI: 10.1007/s00702-013-1031-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  44 in total

Review 1.  MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing.

Authors:  Victor Ambros
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 2.  How microRNAs control cell division, differentiation and death.

Authors:  Eric A Miska
Journal:  Curr Opin Genet Dev       Date:  2005-10       Impact factor: 5.578

3.  Glial cell-line derived neurotrophic factor and neurturin regulate the expressions of distinct miRNA precursors through the activation of GFRalpha2.

Authors:  Li Foong Yoong; Guoqiang Wan; Heng-Phon Too
Journal:  J Neurochem       Date:  2006-08       Impact factor: 5.372

4.  GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons.

Authors:  F Yang; L Feng; F Zheng; S W Johnson; J Du; L Shen; C P Wu; B Lu
Journal:  Nat Neurosci       Date:  2001-11       Impact factor: 24.884

Review 5.  STATs: signal transducers and activators of transcription.

Authors:  J N Ihle
Journal:  Cell       Date:  1996-02-09       Impact factor: 41.582

6.  Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.

Authors:  Gunnar P H Dietz; Paoloa C Valbuena; Birgit Dietz; Katrin Meuer; Patrick Müeller; Jachen H Weishaupt; Mathias Bähr
Journal:  Brain Res       Date:  2006-04-12       Impact factor: 3.252

7.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

8.  6-Hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression.

Authors:  Qinghua Liang; Anthony K F Liou; Yunmin Ding; Guodong Cao; Xiao Xiao; Ruth G Perez; Jun Chen
Journal:  J Neurosci Res       Date:  2004-09-01       Impact factor: 4.164

9.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain.

Authors:  K D Beck; J Valverde; T Alexi; K Poulsen; B Moffat; R A Vandlen; A Rosenthal; F Hefti
Journal:  Nature       Date:  1995-01-26       Impact factor: 49.962

10.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

Authors:  J G Nutt; K J Burchiel; C L Comella; J Jankovic; A E Lang; E R Laws; A M Lozano; R D Penn; R K Simpson; M Stacy; G F Wooten
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

View more
  5 in total

Review 1.  MicroRNAs in Parkinson's disease.

Authors:  Abhishek Singh; Dwaipayan Sen
Journal:  Exp Brain Res       Date:  2017-05-19       Impact factor: 1.972

2.  CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.

Authors:  Khalil Eldeeb; Sandra Leone-Kabler; Allyn C Howlett
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

3.  MicroRNA-26a/Death-Associated Protein Kinase 1 Signaling Induces Synucleinopathy and Dopaminergic Neuron Degeneration in Parkinson's Disease.

Authors:  Ying Su; Man-Fei Deng; Wan Xiong; Ao-Ji Xie; Jifeng Guo; Zhi-Hou Liang; Bo Hu; Jian-Guo Chen; Xiongwei Zhu; Heng-Ye Man; Youming Lu; Dan Liu; Beisha Tang; Ling-Qiang Zhu
Journal:  Biol Psychiatry       Date:  2018-12-19       Impact factor: 13.382

4.  MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.

Authors:  Mingshu Mo; Yousheng Xiao; Shuxuan Huang; Luan Cen; Xiang Chen; Limin Zhang; Qin Luo; Shaomin Li; Xinling Yang; Xian Lin; Pingyi Xu
Journal:  Oncotarget       Date:  2017-01-03

5.  miRNome profiling in Duchenne muscular dystrophy; identification of asymptomatic and manifesting female carriers.

Authors:  Nahla O Mousa; Ahmed A Sayed; Nagia Fahmy; Mariam G Elzayat; Usama Bakry; Ahmed Abdellatif; Waheed K Zahra; Ahmed Osman
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.